Stock ANIP ANI PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights ANI Pharmaceuticals, Inc.

Equities

ANIP

US00182C1036

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
64.9 USD +2.27% Intraday chart for ANI Pharmaceuticals, Inc. +5.84% +17.70%
May. 21 Ani Pharmaceuticals Insider Sold Shares Worth $794,568, According to a Recent SEC Filing MT
May. 20 ANI Pharmaceuticals Launches Kionex Suspension MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
ANI Pharmaceuticals Launches Kionex Suspension
MT
ANI Pharmaceuticals, Inc. Announces the Launch of Kionex Suspension
CI
ANI Pharmaceuticals Seeks M&A
CI
ANI Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024
CI
ANI Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise; Reaffirms Full Year 2024 Earnings, Revenue Guidance
MT
Futures Rebound Pre-Bell Ahead of Earnings, Next Week's Inflation Reports; Asia, Europe Gain
MT
ANI Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
(ANIP) ANI PHARMACEUTICALS Forecasts Fiscal Year 2024 Revenue Range $520M - $542M
MT
(ANIP) ANI PHARMACEUTICALS Forecasts Fiscal Year 2024 EPS Range $4.26 - $4.67
MT
Earnings Flash (ANIP) ANI PHARMACEUTICALS Reports Q1 Revenue $137.4M, vs. Street Est of $126M
MT
Earnings Flash (ANIP) ANI PHARMACEUTICALS Posts Q1 EPS $1.21, vs. Street Est of $1.00
MT
ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension
CI
ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP
CI
ANI Pharmaceuticals Shares Rise After Q4 Adjusted Earnings, Net Revenue Beat Forecasts
MT
ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024
CI
(ANIP) ANI PHARMACEUTICALS Sees Fiscal Year 2024 Revenue Range $520M - $542M
MT
(ANIP) ANI PHARMACEUTICALS Expects Fiscal Year 2024 EPS Range $4.26 - $4.67
MT
Earnings Flash (ANIP) ANI PHARMACEUTICALS Posts Q4 Revenue $131.7M, vs. Street Est of $124.9M
MT
Earnings Flash (ANIP) ANI PHARMACEUTICALS Reports Q4 EPS $1.00, vs. Street Est of $0.86
MT
ANI Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANIP Stock
  4. News ANI Pharmaceuticals, Inc.
  5. Highlights